ESMO Media Releases

Fecal occult blood screening increases high-risk polyp detection by 89%. For high-risk patients, FOBT screening may be more efficient than colonoscopy.

Across Europe, more than 70% of young cancer specialists are showing signs of burnout, the largest survey of its kind has revealed

Canada and Europe sometimes years slower than USA in approving cancer drugs. Breast cancer patients in Eastern Europe have inadequate access to trastuzumab.

Result of a collaborative effort between ESMO and the European School of Oncology (ESO)

Lugano, Switzerland, 15 September 2014 – Poster and Poster Discussion abstracts to be presented at the ESMO 2014 Congress will be published online on Wednesday, 17 September 2014 at 12:00 (CEST) to give you a first glimpse of what you can expect from the European medical oncology Congress, under the leading theme Precision Medicine in Cancer Care.

ESMO Award, ESMO Lifetime Achievement Awarda and Hamilton Fairley Award

ESMO concerned that the proposed EU General Data Protection Regulation could make cancer research impossible and add a significant burden to cancer patients

The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona

Adding the novel MM-398 to standard treatment for metastatic pancreatic cancer patients who have already received gemcitabine improves survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

Fortunato Ciardiello to receive award during the ESMO 16th World Congress on Gastrointestinal Cancer